

Abstract of the Disclosure

There are disclosed compounds of formulae (I) or (II) in which A is selected from the group consisting of (1), (2), (3) and (4); OH, and one of R<sub>1</sub> and R<sub>2</sub> is selected from H, OH and OCH<sub>3</sub>, and the other of R<sub>1</sub> and R<sub>2</sub> is selected from OH and OCH<sub>3</sub>; one of R<sub>3</sub> and R<sub>4</sub> is selected from H, OH and OCH<sub>3</sub>, and the other of R<sub>3</sub> and R<sub>4</sub> is selected from OH and OCH<sub>3</sub>; provided that at least one of the pairs R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>4</sub> are both OH; R<sub>5</sub> is selected from OH and OCH<sub>3</sub>; and ----- denotes a single or double bond; and pharmaceutically acceptable salts and prodrugs thereof. The compounds of the invention are useful for the treatment of hormone-dependent conditions and cancers.

Cross-References to Related Applications

This application is a U.S. national counterpart application of international application serial No. PCT/AU00/00392 filed May 1, 2000, which claims priority to Australian provisional application serial no. PQ0082 filed April 30, 1999.

SEARCHED INDEXED  
JULY 2000  
100-2000




16. (Amended) The method according to claim 13 wherein said hormone dependent condition is selected from the group consisting of hormone dependent cancers, hormone dependent cardiovascular disorders and hormone dependent menopausal disorders.

23. The method according to claim 14 wherein said hormone dependent condition is selected from the group consisting of hormone dependent cancers, hormone dependent cardiovascular disorders and hormone dependent menopausal disorders.

INDS02 MJE 411337v1

17

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :  C07D 311/38, C07C 49/245, 49/248, 49/747, C12N 1/00, A23L 1/30, A61K 31/353, A61P 35/00		A1	(11) International Publication Number: <b>WO 00/66576</b>  (43) International Publication Date: 9 November 2000 (09.11.00)
<p>(21) International Application Number: PCT/AU00/00392</p> <p>(22) International Filing Date: 1 May 2000 (01.05.00)</p> <p>(30) Priority Data: PQ0082 30 April 1999 (30.04.99) AU</p> <p>(71) Applicant (for all designated States except US): G.J. CONSULTANTS PTY LTD [AU/AU]; 21 Kooloona Crescent, West Pymble, NSW 2073 (AU).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (for US only): JOANNOU, George, Eu-stace [AU/AU]; 21 Kooloona Crescent, West Pymble, NSW 2073 (AU).</p> <p>(74) Agent: SPRUSON &amp; FERGUSON; GPO Box 3898, Sydney, NSW 2001 (AU).</p>		<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. With amended claims.</p>	
<p>(54) Title: ISOFLAVONE METABOLITES</p> <p style="text-align: center;">   <span style="margin-left: 200px;">(I)</span>     <span style="margin-left: 800px;">(II)</span> </p> <p style="text-align: center;">   <span style="margin-left: 150px;">(1)</span> <span style="margin-left: 250px;">(2)</span> <span style="margin-left: 450px;">(3)</span> <span style="margin-left: 650px;">(4)</span> </p> <p>(57) Abstract</p> <p>There are disclosed compounds of formulae (I) or (II) in which A is selected from the group consisting of (1), (2), (3) and (4); OH, and one of R<sub>1</sub> and R<sub>2</sub> is selected from H, OH and OCH<sub>3</sub>, and the other of R<sub>1</sub> and R<sub>2</sub> is selected from OH and OCH<sub>3</sub>; one of R<sub>3</sub> and R<sub>4</sub> is selected from H, OH and OCH<sub>3</sub>, and the other of R<sub>3</sub> and R<sub>4</sub> is selected from OH and OCH<sub>3</sub>; provided that at least one of the pairs R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>4</sub> are both OH; R<sub>5</sub> is selected from OH and OCH<sub>3</sub>; and —— denotes a single or double bond; and pharmaceutically acceptable salts and prodrugs thereof. The compounds of the invention are useful for the treatment of hormone-dependent conditions and cancers.</p>			